Sun Pharmaceutical Industries Limited, commonly known as Sun Pharma, is one of India's largest and most renowned pharmaceutical companies. Founded in 1983 by Dilip Shanghvi, the company has grown to become a global leader in the pharmaceutical industry, offering a diverse range of products across various therapeutic segments.

Sun Pharma was established in 1983 with the vision of becoming a major player in the global pharmaceutical market. Dilip Shanghvi’s goal was to create a company that would not only produce high-quality pharmaceutical products but also focus on innovation and patient care. The initial success of Sun Pharma was driven by its commitment to research and development, which allowed the company to offer effective and affordable medicines.

In its early years, Sun Pharma concentrated on the development of psychiatric medications, which established a solid foundation for the company’s growth. The introduction of several successful products in this segment helped Sun Pharma build a strong market presence.

The 1990s and 2000s marked a period of aggressive expansion for Sun Pharma, characterized by a series of strategic acquisitions. These acquisitions were instrumental in enhancing Sun Pharma’s product portfolio and expanding its global footprint. Notable acquisitions during this period included the purchase of companies such as Caraco Pharmaceutical Laboratories in 1997 and Taro Pharmaceutical Industries in 2010.

These acquisitions allowed Sun Pharma to diversify its product offerings and enter new markets, thereby establishing a significant international presence. The acquisition of Taro Pharmaceutical Industries, in particular, was a landmark event that helped Sun Pharma expand its reach in the United States and other international markets.

Sun Pharma has maintained a strong emphasis on research and development, which has been a cornerstone of its success. The company invests heavily in R&D to develop new therapies and improve existing treatments. Sun Pharma’s R&D efforts are focused on several therapeutic areas, including oncology, dermatology, and cardiology.

In recent years, Sun Pharma has made significant advancements in the development of complex generics and novel drug delivery systems. This focus on innovative research positions Sun Pharma as a leader in pharmaceutical innovation.

In recent years, Sun Pharma has continued to build on its legacy of growth and innovation. The company has launched new products, expanded its global presence, and strengthened its position in key therapeutic areas. Looking ahead, Sun Pharma aims to continue its growth trajectory through strategic investments in new technologies and the exploration of emerging markets.

Sun Pharma’s future strategy includes a focus on enhancing its R&D capabilities and expanding its market presence through both organic growth and strategic acquisitions. The company is committed to leveraging its strengths to achieve sustained success in the global pharmaceutical industry.

From 2016 to 2018, Sun Pharma launched some of its new products in the USA. It launched its first branded ophthalmic product, BromSite in 2016. In 2017, the company launched its specialty product [Odomzo](https://en.wikipedia.org/wiki/Odomzo" \o "Odomzo) and then in 2018 another specialty product [Ilumya](https://en.wikipedia.org/wiki/Ilumya" \o "Ilumya) (tildrakizumab-asmn) was launched to treat moderate-to-severe plaque psoriasis.

In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence. The company entered the Greater China market by partnering with China Medical System Holdings as well as launched a speciality product, [CEQUAa](https://en.wikipedia.org/wiki/Cequa" \o "Cequa), in the United States for the treatment of dry eyes.

Sun Pharmaceutical Industries Limited has established itself as a global leader in the pharmaceutical industry through its commitment to innovation, high-quality products, and strategic growth initiatives. With a strong foundation built on early successes and a forward-looking approach to future opportunities, Sun Pharma is well-positioned for continued success in the global market.